Original Article

**Fumaria parviflora** improves liver damage and lipid profile changes in STZ-induced diabetic rats

Fateme Kooshki\textsuperscript{1,2,3}, Hamid Reza Niazkar\textsuperscript{4}, Shabnam Shirazi\textsuperscript{1,2}, Vahid Asghari Azar\textsuperscript{5}, Maryam Moghimian\textsuperscript{6}, Arash Karimi\textsuperscript{1,2,3}*

1. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
2. Nutrition Research Center, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
3. Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
4. Student Research Committee, Gonabad University of Medical Sciences, Gonabad, Iran
5. Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
6. Department of Physiology, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran

**Abstract**

**Introduction:** Chemical drugs and herbal medicine play a significant role in the management of diabetes mellitus complications. The aim of this study was to investigate the effects of **Fumaria parviflora** as an herbal source and glibenclamide as a chemical drug, on the liver tissue of diabetic rats.

**Methods:** Male Wistar rats (n=32) were classified randomly into four groups (8/group), including control, diabetic (induced by 50mg/kg streptozocin), 250mg/kg hydroalcoholic extract of **Fumaria parviflora** (DFP) and 5mg/kg glibenclamide groups. After 21 days of treatment, liver tissues and blood samples were stored at \(-80^\circ\text{C}\) to test lipid profile, liver enzymes and some oxidative stress markers.

**Results:** In the diabetic group compared to the control group, the activities of SOD and GPx and also the serum levels of alkaline phosphatase were significantly decreased, while the levels of malondialdehyde, alanine aminotransferase and aspartate transaminase enhanced. Treatment with DFP and glibenclamide could manage the levels of all mentioned-parameters. Furthermore, in both treated groups, the rate of damages in the liver of rats reduced compared to the diabetic group.

**Conclusion:** According to the obtained results, the administration of DFP or glibenclamide could ameliorate the deleterious effects of diabetes mellitus on some investigated-parameters. As there were no difference between DFP and glibenclamide effects, **Fumaria parviflora** could be considered as an alternative drug, at least for the diabetic complications examined in this study. However, further investigation is needed.

http://dx.doi.org/10.32598/ppj.24.3.80

**Introduction**

Diabetes Mellitus (DM) is one of the most important diseases among metabolic disorders (American diabetic association, 2017). Both types of diabetes (type 1 and type 2) are caused by the lack of insulin production, insulin resistance and the gradual
degradation of pancreatic β-cells (American diabetic association, 2017). It is estimated that the number of people with DM will increase to 439 million adults by 2030 (Koye et al., 2018). Insufficient insulin and hyperglycemia, which is resulted from a lack of insulin, could disrupt carbohydrate, lipid and protein metabolism (American diabetic association, 2017; Abtahi-Eivari et al., 2020), leading to damage of various organs including cardiovascular system, reproduction system, liver, kidneys and eyes (Almalki and Alghamdi, 2019; Rawshani et al., 2017; Sauder et al., 2019; Shoorei et al., 2019). In diabetic patients, dyslipidemia with a prevalence of 72–85%, is appeared due to insulin deficiency and insulin resistance (American diabetic association, 2017). Also, hyperglycemia is led to several abnormalities in lipid metabolisms such as hypertriglyceridemia, elevated-levels of very-low-density lipoprotein (VLDL), LDL, chylomicron and decreased-level of high-density lipoprotein (HDL) (American diabetic association, 2017). On the other hand, hyperglycemia could increase the accumulation of free fatty acids in the liver and stimulate the production of hepatic triglyceride via regulating lipogenesis and reducing oxidation of free fatty acids, which is resulted in lipotoxicity and steatosis (American diabetic association, 2017; Chaudhury and Aggarwal, 2018).

It has been reported that following DM in serum, levels of alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) which mainly produce in the liver, are increased (Fraser et al., 2009). Interestingly, the higher serum concentration of GGT is considered as a useful marker for the development of DM and oxidative stress (Lee et al., 2004). Nowadays, physicians are using chemical anti-diabetic drugs, including glibenclamide, sulfonylurea, thiazolidinediones and α-glucosidase, to control blood glucose and inhibition of diabetes complications (Gamble et al., 2018; Srinivasan et al., 2018). However, using of mentioned-drugs could be associated with serious side-effects (Chidambaram et al., 2018).

Medicinal plants that are currently using to the management of blood glucose, work via various mechanisms such as decreasing insulin resistance and levels of oxidative stress, caused by free radicals in the pancreas tissue (Abtahi-Evari et al., 2017). *Fumaria parviflora* L, which is belonged to the Papaveraceae family, is an herb annually grows in vast areas of Pakistan, Iran, Indian and Turkey (Al-Snafi, 2018; Shokoohi et al., 2018). Traditionally, it has been used to the treatment of several diseases related to skin, liver and bile duct (Al-Snafi, 2018). High-performance liquid chromatography analysis showing that *Fumaria parviflora* is contained various amounts of compounds including fumaritine, paprafuminic, paparine, fumaranine, cotropsine, adlumidinecine, parufumine and etc (Al-Snafi, 2018; Kumar et al., 2009; Tripathi et al., 2010). Therefore, it has a wide range of pharmacological properties including antioxidant and anti-inflammatory activities (Al-Snafi, 2018).

A high dose of *Fumaria parviflora* had protective effects on hepatocytes against liver injury induced by carbon tetrachloride, and also could reduce liver enzymes such as ALP, serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase (Alqasoumi et al., 2009). Administration of methanolic extract of *Fumaria parviflora* decreased the level of blood glucose in diabetic rats (Fathiazad et al., 2013). Treatment with *Fumaria parviflora* could also reduce the levels of malondialdehyde (MDA), TNF-α, IL-6 and IL-1 in rats, in which inflammation was induced by aspirin (Rizvi et al., 2017). Although in traditional Iranian medicine *Fumaria parviflora* had been used as a source for the treatment of liver and bile ducts disorders, recent studies reported that it could affect the lipid profile (decrease the levels of LDL, triglycerides [TG] and cholesterol and increase HDL level), blood glucose and liver enzymes in diabetic patients (Al-Snafi, 2018; Osadibee et al., 2014). Because few studies have been done on the anti-diabetic effects of *Fumaria parviflora*, the purpose of this study was to investigate the effect of *Fumaria parviflora* (a traditional herbal medicine) on liver tissue and biochemical factors in diabetic rats; also the glibenclamide (a chemical drug) was used as control.

**Materials and methods**

**Plant material**

*Fumaria parviflora* leaves were collected from Fars Province, Kazeroun City, by a botanist in July 2017. The identity of this plant was approved at the Central Herbarium of Tehran University. To provide the whole extract of *Fumaria parviflora* leaves, 1kg of leaves was dried at 25°C. After grinding for extraction from
the dried plants, obtained powder was dissolved in 2 liters of ethanol (96%) and then kept at room temperature for 48h (Shokoohi et al., 2018). The solution was filtered over this period after regularly shaking. Then, it was centrifuged for 5min at 1008g. At the final procedure, the solution was poured into an open-top container and the solvent was dry out (Shokoohi et al., 2018). However, 200g of a semisolid extract was achieved from 1kg of leaves. Finally, the extract was dissolved in normal saline for preparing the appropriate concentration.

**Liver enzyme biochemical assays**

The levels of liver enzymes, alanine transaminase (ALT), alkaline phosphatase (ALP) and aspartate aminotransferase (AST) were measured using commercial kits (Parsazmun, Iran) (Kiafar et al., 2018).

**Measurement of the oxidative stress markers**

MDA level was assessed for investigation the lipid peroxidation in the liver. In order to provide a solution of "TBA-TCA-HCL", 375mg of thiobarbituric acid (TBA) was solved in 2ml of HCL, next added into 100ml of 15 percent trichloroacetic acid (TCA) (Delkhosh et al., 2019; Shokoohi et al., 2019). A water bath (50ºC) was used for dissolving the sediment, therefore the solution of potassium chloride (5.1%) used to immediately obtain a homogenized mixture (10%). Then, 1ml of the homogenized tissue was blended with 2ml of TBA-TCA-HCl solution and warmed in boiling water for 45min (Shokoohi et al., 2020). After being cold, it was centrifuged at 1000rpm for 10min. Spectrophotometer (Biospect) was used to read the absorption at 532nm. Besides, the levels of superoxide dismutase (SOD) and glutathione peroxidase (GPx) were measured according to the methods developed by Sun et al. (1988) and Paglia and Valentine (1967), respectively, using the commercial kits (Ransod and Ransel, Randox Com, UK).

**Histopathological investigation**

The liver samples were fixed in 10% formalin for 4 weeks and the fixative solution was weekly replaced with the refresh solution. After fixation, samples dehydrated and embedded in paraffin to 5μm cutting by a microtome. Finally, all of the samples stained with hematoxylin-eosin. For histopathological analysis, some slides were used to assess the histological changes and other slides were used to evaluate the edema, rupture, hemorrhage in central veins, dilatation in sinusoid and pyknotic nuclei.

**Statistical analysis**

All of the obtained values were analyzed by the SPSS software version 18 (SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was applied to examine whether the obtained data were normality distributed. The differences between the experimental groups were analyzed by one-way analysis of
The effects of *Fumaria parviflora* and glibenclamide on status of antioxidant enzymes

DM led to a significant increase in the amount of MDA and a significant decrease in the activities of SOD and GPx (*P*<0.02, Table 2). Treatment with *Fumaria parviflora* and glibenclamide significantly decreased the level of MDA and increased the activities of SOD and GPx (*P*<0.05). There was no significant difference for all mentioned parameters between two treated groups (*P*>0.05, Table 2).

The effects of *Fumaria parviflora* extract and glibenclamide on serum level of AST, ALT and ALP

These results are presented in Table 3. In the DC group, the levels of ALT and AST were higher than the DG and DFP groups (*P*<0.03), while, the level of ALP decreased (*P*<0.02). In both treated groups (DG and DFP), the amount of ALT and AST significantly decreased compared to the DC group (*P*<0.04) and also the level of ALP increased (*P*<0.04). There was

---

Table 1: Effects of *Fumaria parviflora* and glibenclamide on lipid profile in diabetic rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>Cholesterol (Mean ± SD)</th>
<th>HDL (Mean ± SD)</th>
<th>LDL (Mean ± SD)</th>
<th>TG (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>53.71 ± 8.92</td>
<td>43.54 ± 5.27</td>
<td>24.14 ± 2.32</td>
<td>33.21 ± 3.73</td>
</tr>
<tr>
<td>DC</td>
<td>84.57 ± 11.13 *</td>
<td>21.92 ± 2.43</td>
<td>41.27 ± 4.53</td>
<td>70.05 ± 6.48</td>
</tr>
<tr>
<td>DFP</td>
<td>66.42 ± 9.01 †</td>
<td>35.24 ± 4.67</td>
<td>30.12 ± 3.07</td>
<td>45.57 ± 4.18</td>
</tr>
<tr>
<td>DG</td>
<td>71.19 ± 10.07 ††</td>
<td>31.32 ± 5.14</td>
<td>32.25 ± 2.98</td>
<td>50.28 ± 4.96</td>
</tr>
</tbody>
</table>

Control: the control group received normal saline; DC: the diabetic control group received normal saline; DG: the diabetic control group received glibenclamide (5mg/kg); DFP: the diabetic group received a hydroalcoholic extract of *Fumaria parviflora* (250mg/kg). SD: Standard deviation. *P*≤0.03 shows a significant difference compared to the control group. †P<0.05 shows a significant difference compared to the DC group.

Table 2: Effects of *Fumaria parviflora* and glibenclamide on antioxidant properties in diabetic rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>SOD (U/ml) (Mean ± SD)</th>
<th>GPx (U/ml) (Mean ± SD)</th>
<th>MDA (nM) (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>3.24 ± 0.42</td>
<td>24.62 ± 3.39</td>
<td>11.38 ± 1.07</td>
</tr>
<tr>
<td>DC</td>
<td>1.02 ± 0.34 *</td>
<td>8.08 ± 1.01 †</td>
<td>27.07 ± 3.12 †</td>
</tr>
<tr>
<td>DFP</td>
<td>1.87 ± 0.11 ††</td>
<td>19.82 ± 2.76 †</td>
<td>18.01 ± 2.81 †</td>
</tr>
<tr>
<td>DG</td>
<td>1.58 ± 0.12 ††</td>
<td>15.03 ± 2.91 †</td>
<td>20.77 ± 2.05 †</td>
</tr>
</tbody>
</table>

Control: the control group received normal saline; DC: the diabetic control group received normal saline; DG: the diabetic control group received glibenclamide (5mg/kg); DFP: the diabetic group received a hydroalcoholic extract of *Fumaria parviflora* (250mg/kg). SD: Standard deviation. *P*≤0.02 shows a significant difference compared to the control group. †P<0.05 shows a significant difference compared to the DC group.

---

The variance (ANOVA), followed by Tukey’s post hoc test. The values are expressed as the mean±SD and the level of statistical significance was set at *P*<0.05.

**Results**

The effects of *Fumaria parviflora* and glibenclamide on blood parameters, including HDL, LDL, cholesterol and TG

Table 1 shows the amount of the earlier-mentioned parameters. According to Table 1, in the diabetic group compared to the control group, the serum level of HDL was significantly decreased (*P*<0.03), while the levels of LDL, cholesterol and TG increased (*P*≤0.03). In both treated groups (DG and DFP) compared to the diabetic group, the serum HDL level improved (*P*<0.05), while serum levels of LDL, cholesterol and TG decreased (*P*<0.05). In this regard, there was no significant difference for all mentioned parameters between two treated groups (*P*>0.05).
no significant difference for all mentioned parameters between two treated groups ($P>0.05$, Table 3).

### Discussion

Although the primary targets in the treatment of DM are insulin and hypoglycemic agents, finding an ideal effective agent with minimum side-effects has still not been achieved (Hasanpour et al., 2018). Chemical drugs in long-term use have limited efficacy and also various side-effects, including increased fat storage, hypoglycemic shock and wasting the fat tissue at the site of the injection, are predictable (Hasanpour et al., 2018). Nowadays, medicinal plants with antioxidative

<table>
<thead>
<tr>
<th>Groups</th>
<th>ALP (Mean ± SD)</th>
<th>ALT (Mean ± SD)</th>
<th>AST (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>247.32 ± 35.21</td>
<td>71.08 ± 9.25</td>
<td>221.02 ± 21.27</td>
</tr>
<tr>
<td>DC</td>
<td>89.49 ± 13.27 *</td>
<td>167.01 ± 23.62 *</td>
<td>332.24 ± 25.63 *</td>
</tr>
<tr>
<td>DFP</td>
<td>187.75 ± 20.32 †</td>
<td>127.87 ± 14.52 †</td>
<td>258.89 ± 24.09 †</td>
</tr>
<tr>
<td>DG</td>
<td>176.02 ± 21.24 †</td>
<td>134.12 ± 13.58 †</td>
<td>262.39 ± 22.61 †</td>
</tr>
</tbody>
</table>

Control: the control group received normal saline; DC: the diabetic control group received normal saline; DG: the diabetic control group received glibenclamide (5mg/kg); DFP: the diabetic group received a hydroalcoholic extract of *Fumaria parviflora* (250mg/kg). SD: Standard deviation. *$P<0.03$ shows a significant difference compared to the control group. †$P<0.04$ shows a significant difference compared to the DC group.

Fig.1. Representative picture of liver histology stained with hematoxylin and eosin (H&E) in different groups of the study. 1: the control group received normal saline, in this group standard liver architecture is evident; 2: the diabetic control group received normal saline, in this group severe liver damage is apparent; 3: the diabetic group received a hydroalcoholic extract of *Fumaria parviflora* (250mg/kg), in this group there was an improvement in the liver structure; 4: the diabetic control group received glibenclamide (5mg/kg), in this group, there was an improvement in the liver structure.
Studies changes in the liver of diabetic. However, treatment with... products of polyunsaturated fatty acid which have been reported that... important product of polyunsaturated fatty acid oxidation and is one of the main factors of oxidative injury to membrane lipids (Maritim et al., 2003; Seghinsara et al., 2019). However, treatment with *Fumaria parviflora* reduced the level of MDA and enhanced the levels of GPx and SOD, which could possibly be due to the reduced oxidative stress in tissues and the elevated intracellular antioxidant enzyme activities. Therefore, it seems that *Fumaria parviflora* could reinforcement the antioxidant defense system and reduce oxidative stress. Our histological studies showed that DM led to degenerative changes such as edema, rupture, hemorrhage in central veins, dilatation in sinusoids and pyknotic nuclei. In the therapeutic groups (DFP and DG), degenerative changes were decreased in the liver tissue.

Our results showed that the plasma levels of AST and ALT were enhanced in the diabetic group because of the liver damage caused by DM. The levels of two mentioned-enzymes are increased in the diabetic condition and it has been reported that they are directly involved in the conversion of amino acids to keto acids (Kaleem et al., 2008). Studies showed that levels of two mentioned-enzymes (AST and ALT) are increased in the liver of diabetic animals (Kaleem et al., 2008; Rauter et al., 2010). In our study, treatment with *Fumaria parviflora* or glibenclamide could decrease the serum levels of AST and ALT. The elevated protein catabolism, urea formation and gluconeogenesis, which are observed in the diabetic condition, might be caused by the development of transaminases (Hatting et al., 2018). It has been also reported that the elevated level of ALT may be due to the hepatocellular injury caused by oxidative stress (Pradeep et al., 2007). Treatment with *Fumaria parviflora* could modify the levels of mentioned-parameters (Alqasoumi et al., 2009). Therefore, treatment with *Fumaria parviflora* may be involved in the inhibition of gluconeogenesis and......
heptocellular damage. However, we strongly suggest that further studies should be carried out to light out how *Fumaria parviflora* could affect the signaling pathways involved in gluconeogenesis. Furthermore, the serum level of ALP was higher in the diabetic group than the other groups. This issue may be due to the abundance of free radicals which results in the generation of lipid hydroperoxide and cellular injury. By an injury to the hepatocytes, the leakage of transaminases, bilirubin and ALP is initiated. However, the use of *Fumaria parviflora* is quite safe at the applied doses and no signs of toxicity or adverse effects were reported in the treated animals (Alqasoumi et al., 2009; Rizvi et al., 2017).

**Conclusion**

The obtained results of the current study showed that treatment with *Fumaria parviflora* extract and glibenclamide could decrease the levels of cholesterol, LDL and TG in diabetic rats and could balance the antioxidant enzyme status. However, no significant difference was observed for all parameters investigated in the present study between two treated groups, glibenclamide and *Fumaria parviflora*. We suggest other doses of glibenclamide and *Fumaria parviflora* should be further studied and also a combination of two supplements may light out how they work together against diabetes mellitus. For further studies, it is recommended that the effective ingredients of *Fumaria parviflora* extract be identified and determine the role of ingredients in regulating the expression level of apoptotic genes and different signaling pathways. It is also recommended that the MicroRNA involved in the process of apoptosis, which has been reduced by the *Fumaria parviflora*, as well as the expression of genes related to oxidative (such as nuclear factor erythroid 2-related factor-2) and inflammatory pathways (such as nuclear factor kappa B), be performed and finally conducting clinical trials studies.

**Acknowledgments**

This study was received a specific grant from Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

**Conflict of interest**

None.

**References**


Gamble JM, Donnan JR, Chibrikov E, Twelks LK, Midodzi...
Fumaria parviflora and liver damage

Physiol Pharmacol 24 (2020) 221-229 | 228


09603271209095255


Van Wyk BE, Wink M. Medicinal plants of the world (CABI), 2018. https://doi.org/10.1079/9781786393258.0000